Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s

Biogen–Denali Parkinson’s Therapy Falters in Mid-Stage Trial, Shifting Focus to Targeted Subgroups

A recent article by BioPharmaDive highlighted a mid-stage clinical trial that evaluted an investigational Parkinson’s disease therapy co-developed by Biogen and Denali Therapeutics, and that failed to meet its primary and secondary endpoints, prompting both companies to halt further development of the drug for the broader Parkinson’s population. However, Denali plans to continue studying the […]

Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s

Biogen and Denali Therapeutics have discontinued clinical development of BIIB122, an LRRK2 inhibitor, for idiopathic Parkinson’s disease.